1. Kovesdy CP. Epidemiology of chronic kidney disease: an update. Kidney International Supplements 2022; 12: 7–11. https://doi.org/10.1016/j.kisu.2021.11.003
2. Rossing P. Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Kidney International Supplements 2022; 12: 27–35. https://doi.org/10.1016/j.kisu.2021.11.005
3. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020. Accessed September 17th, 2022. https://adr.usrds.org/2020/end-stage-renal-disease/11-international-comparisons
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 12;352(9131):837 − 53.
5. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease. Challenges, Progress, and Possibilities. CJASN 2017; 12(12): 2032–2045. https://doi.org/10.2215/CJN.11491116
6. Brenner BM, Cooper ME, de Zeeuw D, Kaene WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861–869. https://pubmed.ncbi.nlm.nih.gov/11565518/
7. Fried LF, Emanuele N, Zhang JH, Brophy M, Conbner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013; 369:1892–1903. https://www.nejm.org/doi/10.1056/NEJMoa1303154
8. Parving HH, Brenner BM, McMurray JJ, McMurray JV, Zeeuw D, Haffner SM,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367:2204–2213. https://www.nejm.org/doi/10.1056/NEJMoa1208799
9. Luther JM and Fogo AB. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney International Supplements 2022; 12: 63–68. https://doi.org/10.1016/j.kisu.2021.11.006
10. Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015; 24:417– 424. https://pubmed.ncbi.nlm.nih.gov/26083526/
11. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos,G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013; 34:2453– 2463. https://pubmed.ncbi.nlm.nih.gov/23713082/
12. FDA (2021). FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complications in Adults with Chronic Kidney Disease Associated with Type 2 Diabetes. Available at: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease (Accessed September 17, 2022).
13. Zhang M, Bao W, Zheng Q, Wang Y, and Sun L. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front. Pharmacol. 13:819327. https://www.frontiersin.org/articles/10.3389/fphar.2022.819327/full
14. Fu Z, Geng X, Chi K, Song C, Wu D, Liu D, et al. Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis. Ann Palliat Med 2021;10(7):7428–7439. https://dx.doi.org/10.21037/apm-21-763
15. SAMIT GHOSAL, Binayak Sinha. Finerenone is a new addition to renal protection in patients with Type 2 diabetes and chronic kidney disease: A random-effects model meta-analysis. PROSPERO 2022 CRD42022360003 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022360003
16. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015; 314(9):884 − 94. doi: 10.1001/jama.2015.10081. https://pubmed.ncbi.nlm.nih.gov/26325557/
17. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383:2219-29. https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
18. Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications 2017; 31:758 − 65. https://pubmed.ncbi.nlm.nih.gov/28025025/
19. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N. Engl. J. Med. 2021; 385: 2252–2263. doi:10.1056/NEJMoa2110956 https://pubmed.ncbi.nlm.nih.gov/34449181/
20. Rangaswami J, Bhalla V, Boer IH, Staruschenko A, Sharp JA, Singh RR, et al. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation 2020;142: e265–e286. https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000920
21. Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982; 21:98–101. https://pubmed.ncbi.nlm.nih.gov/7043053/
22. Bauersachs J, Jaisser F, and Toto R. Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hypertension. 2015; 65:257–263. https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.114.04488